Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma

NCT03775525 is registered in ClinicalTrials.gov with Genzada Pharmaceuticals USA, Inc. as lead sponsor.

NCT NCT03775525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03775525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Lead sponsor
Genzada Pharmaceuticals USA, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2019
Completion date
December 31, 2023
Enrollment
127 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, basal cell carcinoma, breast cancer, cancer of stomach, colo-rectal cancer, cutaneous squamous cell carcinoma, cutaneous t cell lymphoma, cutaneous t-cell lymphoma, gastric cancer, head and neck squamous cell carcinoma, lymphoma, pancreatic cancer, prostate cancer metastatic, sarcoma, solid carcinoma, solid carcinoma of stomach, solid tumor